By Chad Terhune and Dan Levine (Reuters) -One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy ...

Merck & Co., Inc. (NYSE:MRK) is one of the best Dow stocks to invest in. On June 9, the company announced that its drug, ...

The stock's fall snapped a three-day winning streak.

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...

Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...

Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety ...

Merck & Co., Inc. ( NYSE: MRK) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:00 AM ET Dean Y. Li - Executive VP & President of Merck Research Laboratories Robert M. Davis - ...

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

Merck KGaA has shed more light on the failure of its lupus drug in one cohort of patients, while pointing to secondary ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...